ICU Medical Inc
$55.8K 117 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
US Oncology Corporate, Inc.
US Oncology Corporate, Inc. reported $55,901.33 across General Payments, Research, and Ownership to 259 physicians and teaching hospitals across 259 transactions.
- $55.9K Below-median payer
- All-tracks total
- 259 Above-median volume
- Transactions
- 259 Above-median reach
- Recipients
- −$13.0K
- General Payments vs PY2023
US Oncology Corporate, Inc. reported $55,901.33 across all CMS Open Payments tracks (General + Research + Ownership) to 259 physicians and teaching hospitals in Program Year 2024 - ranking #1324 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $55,901.33, averaging $215.84 per recipient.
US Oncology Corporate, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
10/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer us-oncology-corporate-inc US Oncology Corporate, Inc.
$55.9K · #1324/1,925 · 0.0% industry · PY2024
- TOT $55.9K
- RANK #1324
- SHARE 0.0%
- TXN 259
- RCP 259
- CAT 3
- GEN $55.9K
- ΔGEN −$13.0K
- TOP1 4.0%
- PY 2024
Volume peers
Nearest volume peer: ICU Medical Inc ($55.8K)
US Oncology Corporate, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
US Oncology Corporate, Inc.'s CMS-reported General Payments decreased by $13.0K (−18.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: US ONCOLOGY CORPORATE, INC.PY2023: US ONCOLOGY CORPORATE, INC.PY2024: US Oncology Corporate, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $68,933.49
- PY2024
- $55,901.33
What the Data Shows for US Oncology Corporate, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For US Oncology Corporate, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Food and Beverage" leads the 3-category general-payment breakdown below at $32.9K (58.8% of General Payments, 197 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
US Oncology Corporate, Inc. made 3 types of general payments. "Food and Beverage" is the largest category at $32.9K, 58.8% of General Payments.
How US Oncology Corporate, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $32.9K | 197 | 58.8% |
| Travel and Lodging | $22.6K | 48 | 40.4% |
| Gift | $463.40 | 14 | 0.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $9,986.13 (17.9%) of $55,901.33 in this company's General Payments records across 132 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for US Oncology Corporate, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Sanford Chen
$2,226.12 across 3 reported transactions
- 2
Jeffrey B Minkovitz
$2,080.22 across 3 reported transactions
- 3
Cameron Mclure Stone
$1,944.21 across 3 reported transactions
- 4
Matthew Melton Cole
$1,886.49 across 3 reported transactions
- 5
Raj K Maturi
$1,849.09 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
US Oncology Corporate, Inc.'s spend rank (#1324 of 1,925, bottom 31% by spend) and concentration rank (#1,547 of 1,838, bottom 16% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Taiho Oncology, Inc. : $844.4K total payments, HHI 215
- Accord Healthcare, Inc. : $181.0K total payments, HHI 215
- Cgg Medical Inc : $149.7K total payments, HHI 214
- QOL Medical, LLC : $693.7K total payments, HHI 214
- Mentor Worldwide LLC : $1.0M total payments, HHI 213
- Avation Medical, Inc. : $4.0K total payments, HHI 213
- US Oncology Corporate, Inc. (this company) : $55.9K total payments, HHI 209
- Southern Edge Orthopaedics, Inc. : $9.9K total payments, HHI 207
- Aurinia Pharma U.S., Inc. : $1.0M total payments, HHI 207
- Darby Dental Supply, LLC : $229.5K total payments, HHI 207
- Incyte Corporation : $13.1M total payments, HHI 206
- Mitsubishi Tanabe Pharma America, Inc. : $415.3K total payments, HHI 205
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as US Oncology Corporate, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about US Oncology Corporate, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with US Oncology Corporate, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Fidia Pharma USA Inc.
$55.5K 2,274 recipients
Compare payment profiles
Dentium Co., Ltd
$56.4K 14 recipients
Compare payment profiles
Nuvascular Inc.
$55.0K 0 recipients
Compare payment profiles
FKG Dentaire Sarl
$56.8K 12 recipients
Compare payment profiles
exocad America, Inc.
$54.9K 13 recipients
Compare payment profiles
Put this to use
US Oncology Corporate, Inc. ranks #1324 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just US Oncology Corporate, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.